Abstract：
The global spread of COVID-19 has prompted the development of vaccines. A recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by Chinese scientists has been authorized for use as a prime and booster dose in China and several other countries.
We searched published articles as of 4 May 2023, on PubMed using keywords related to Adenovirus vector, vaccine, and SARS-CoV-2. We reported the progress and outcomes of Ad5-nCov, including vaccine efficacy, safety, immunogenicity based on pre-clinical trials, clinical trials, and real-world studies for primary and booster doses.
Ad5-nCoV is a significant advancement in Chinese vaccine development technology. Evidence from clinical trials and real-world studies has demonstrated well-tolerated, highly immunogenic, and efficacy of Ad5-nCoV in preventing severe/critical COVID-19. Aerosolized Ad5-nCoV, given via a novel route, could elicit mucosal immunity and improve the vaccine efficacy, enhance the production capacity and availability, and reduce the potential negative impact of preexisting antibodies. However, additional research is necessary to evaluate the long-term safety and immunogenicity of Ad5-nCoV, its efficacy against emerging variants, its effectiveness in a real-world context of hybrid immunity, and its cost-effectiveness, particularly with respect to aerosolized Ad5-nCoV.
We searched published articles as of 4 May 2023, on PubMed using keywords related to Adenovirus vector, vaccine, and SARS-CoV-2. We reported the progress and outcomes of Ad5-nCov, including vaccine efficacy, safety, immunogenicity based on pre-clinical trials, clinical trials, and real-world studies for primary and booster doses.
Ad5-nCoV is a significant advancement in Chinese vaccine development technology. Evidence from clinical trials and real-world studies has demonstrated well-tolerated, highly immunogenic, and efficacy of Ad5-nCoV in preventing severe/critical COVID-19. Aerosolized Ad5-nCoV, given via a novel route, could elicit mucosal immunity and improve the vaccine efficacy, enhance the production capacity and availability, and reduce the potential negative impact of preexisting antibodies. However, additional research is necessary to evaluate the long-term safety and immunogenicity of Ad5-nCoV, its efficacy against emerging variants, its effectiveness in a real-world context of hybrid immunity, and its cost-effectiveness, particularly with respect to aerosolized Ad5-nCoV.
摘要：
■COVID-19的全球传播推动了疫苗的开发。由中国科学家开发的重组腺病毒5型载体COVID-19疫苗（Ad5-nCoV）已被授权在中国和其他几个国家用作主要和加强剂量。
■我们使用与腺病毒载体相关的关键字在PubMed上搜索了2023年5月4日发表的文章，疫苗，和SARS-CoV-2.我们报告了Ad5-nCov的进展和结果，包括疫苗功效，安全,基于临床前试验的免疫原性，临床试验,以及主要剂量和加强剂量的真实世界研究。
■Ad5-nCoV是中国疫苗开发技术的重大进步。临床试验和现实世界研究的证据表明，耐受性良好，高度免疫原性，Ad5-nCoV预防重症/危重症COVID-19的疗效。雾化Ad5-nCoV,通过一条新颖的路线，可以引起粘膜免疫，提高疫苗的疗效，提高生产能力和可用性，并减少预先存在的抗体的潜在负面影响。然而,需要进一步的研究来评估Ad5-nCoV的长期安全性和免疫原性，它对新兴变体的功效，它在混合免疫的现实环境中的有效性，以及它的成本效益，特别是关于雾化的Ad5-nCoV。
■我们使用与腺病毒载体相关的关键字在PubMed上搜索了2023年5月4日发表的文章，疫苗，和SARS-CoV-2.我们报告了Ad5-nCov的进展和结果，包括疫苗功效，安全,基于临床前试验的免疫原性，临床试验,以及主要剂量和加强剂量的真实世界研究。
■Ad5-nCoV是中国疫苗开发技术的重大进步。临床试验和现实世界研究的证据表明，耐受性良好，高度免疫原性，Ad5-nCoV预防重症/危重症COVID-19的疗效。雾化Ad5-nCoV,通过一条新颖的路线，可以引起粘膜免疫，提高疫苗的疗效，提高生产能力和可用性，并减少预先存在的抗体的潜在负面影响。然而,需要进一步的研究来评估Ad5-nCoV的长期安全性和免疫原性，它对新兴变体的功效，它在混合免疫的现实环境中的有效性，以及它的成本效益，特别是关于雾化的Ad5-nCoV。
